NCT01199705 - Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

November 30, 2011

Conditions

Primary Immune Deficiency

Interventions

BIOLOGICAL

Immune Globulin Subcutaneous (Human) (SCIG)

IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.

Trial Locations (10)

466-8560

Study site, Nagoya

260-8677

Study site, Chiba

501-1194

Study site, Gifu

060-8648

Study site, Sapporo

980-8574

Study site, Sendai

812-8582

Study site, Fukuoka City

570-8507

Study site, Moriguchi

534-0021

Study site, Osaka

343-8555

Study site, Koshigaya

359-8513

Study site, Tokorozawa